Physician profile
Xin Ru
NPI 1952008906
$1,306.27
in general payments reported to CMS, 2019-2025
11 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $329 · 2024: $425 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.77 |
| Education | $166.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.64 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $166.50 | 2023-2024 | |
| Amgen INC. | $131.67 | 2024-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $95.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $92.12 | 2024-2025 | |
| Biosense Webster, INC. | $76.96 | 2023 | Carto 3 |
| Lexicon Pharmaceuticals, INC. | $66.07 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $65.89 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $58.19 | 2023-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $32.41 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.40 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Ru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.